A Phase II Study of Patupilone (EPO906A) as a Second Line Chemotherapy in Patients With Hormone Refractory Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2010
At a glance
- Drugs Patupilone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 03 Nov 2010 Additional lead trial centre, investigator identified as reported by ClinicalTrials.gov.
- 03 Nov 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.